Icon Group adopts first-to-market RTsafe solutions to support advanced radiosurgery across Australia
RTsafe, a leading medical technology company specialising in quality assurance (QA) solutions for radiation therapy, and Icon Group (Icon), a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom, today announced the purchase of two RTsafe PRIME phantoms. These are the first PRIME phantoms to be installed in Australia, underscoring a shared commitment to safety, precision, and innovation in cancer care.
The PRIME phantom is an anthropomorphic, 3D-printed head phantom that combines true-to-life human anatomy with advanced point, 2D and 3D dosimetry to deliver true end-to-end quality assurance. Used together with RTsafe’s independent remote dosimetry services, it enables a comprehensive verification of complex stereotactic and other high-precision radiotherapy treatments, assessing the entire treatment chain from imaging and planning through patient setup and dose delivery. The RTsafe PRIME phantom and the related RTsafe dosimetry services, is also the exclusive phantom used by the International Stereotactic Radiosurgery Society (ISRS) in its ISRS Certification Service, providing centres with a recognised, standardised pathway to demonstrate the accuracy and robustness of their radiosurgery programs.
Icon has acquired the PRIME phantoms to support its existing quality assurance programs for stereotactic radiosurgery across its Icon Cancer Centre locations in Australia. Each PRIME phantom will be deployed across the network, enabling local teams to rigorously verify complex treatment plans as they introduce and expand advanced stereotactic radiosurgery programs across their fleet of Varian linacs (TrueBeam, Halcyon and Ethos), Elekta’s Leksell Gamma Knife and Accuray’s CyberKnife. By partnering with RTsafe, Icon strengthens its ability to provide clinicians with the confidence to deliver advanced treatment techniques safely and effectively translating into greater reassurance for patients and their families.
“Our collaboration with Icon reflects a shared ambition to continually elevate the standards of cancer care,” said Evangelos Pappas, Founder and CSO of RTsafe. “At RTsafe, our goal is to bring certainty to radiotherapy—giving clinicians robust, independent evidence that complex treatments are delivered as intended, and giving patients peace of mind that their safety is carefully safeguarded at every step.”
“At Icon we have a strong track-record and commitment to investing in the latest cutting-edge treatments and technologies to improve the way we deliver care,” said Trent Aland, Icon Group’s Executive Manager – Clinical Care. “The introduction of these phantoms will further enhance our quality assurance and enable the safe delivery of complex and highly advanced treatments for the benefit of teams and our patients.”
Looking ahead, the collaboration is expected to open new avenues for clinical and research initiatives across Icon Group’s network in Australia and its broader footprint in Asia-Pacific and the UK, highlighting the role of international partnerships in advancing global standards of cancer care.
RTsafe is a medical technology company that focuses on improving the safety and accuracy of radiotherapy through innovative quality assurance solutions. Combining deep expertise in medical physics with highly accurate 3D printing and advanced dosimetry, RTsafe develops anatomically realistic phantoms and end-to-end QA services for commissioning, benchmarking and patient-specific verification in stereotactic radiosurgery and other complex radiotherapy techniques. RTsafe works with treatment centres and industry partners worldwide to support safer, more effective radiation therapy.
Icon Group is a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom.
Icon is built on a strong but simple mission – to deliver the best care possible to as many people as possible, as close to home as possible. The group brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research, theranostics, pharmacy and compounding to deliver a truly integrated, end-to-end seamless service for cancer patients. With more than 3,500 team members, a network of 350 plus doctors, over 55 cancer centres, six compounding facilities and operational support of 70 plus pharmacies, Icon is delivering world-leading care and helping address the global cancer burden.